BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311-318. [PMID: 23615394 DOI: 10.1159/000348325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Tabone M, Calvo A, Russolillo N, Langella S, Carbonatto P, Lo Tesoriere R, Richetta E, Pellerito R, Ferrero A. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol 2020;11:84-90. [PMID: 32175109 DOI: 10.21037/jgo.2019.06.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Lau WY, Zhou WP. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study: reply. World J Surg 2014;38:1247-8. [PMID: 24271695 DOI: 10.1007/s00268-013-2353-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Mizandari M, Azrumelashvili T, Paksashvili N, Kikodze N, Pantsulaia Ia, Janikashvili N, Chikovani T. Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation. Case Reports Hepatol 2016;2016:6843121. [PMID: 27579192 DOI: 10.1155/2016/6843121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Braat MN, van Erpecum KJ, Zonnenberg BA, van den Bosch MA, Lam MG. Radioembolization-induced liver disease: a systematic review. European Journal of Gastroenterology & Hepatology 2017;29:144-52. [DOI: 10.1097/meg.0000000000000772] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 8.2] [Reference Citation Analysis]
5 Yang Z, Zou R, Zheng Y, Qiu J, Shen J, Liao Y, Zhang Y, Wang C, Wang Y, Yuan Y, Li K, Zuo D, He W, Liu W, Li B, Yuan Y. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol 2019;29:5752-62. [PMID: 30993438 DOI: 10.1007/s00330-019-06157-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
6 Seidensticker M, Fabritius MP, Beller J, Seidensticker R, Todica A, Ilhan H, Pech M, Heinze C, Powerski M, Damm R, Weiss A, Rueckel J, Omari J, Amthauer H, Ricke J. Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization. Cancers (Basel) 2021;13:1992. [PMID: 33919073 DOI: 10.3390/cancers13091992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68:724-32. [PMID: 29331342 DOI: 10.1016/j.jhep.2017.12.026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
8 Radunz S, Treckmann J, Baba HA, Best J, Müller S, Theysohn JM, Paul A, Benkö T. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017;22:215-21. [PMID: 28408731 DOI: 10.12659/aot.902595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
10 Venkatanarasimha N, Gogna A, Tong KTA, Damodharan K, Chow PKH, Lo RHG, Chandramohan S. Radioembolisation of hepatocellular carcinoma: a primer. Clin Radiol. 2017;72:1002-1013. [PMID: 29032802 DOI: 10.1016/j.crad.2017.07.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
11 Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825-1833. [PMID: 24499831 DOI: 10.1245/s10434-014-3510-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
12 Mohan G, T P AH, A J J, K M SD, Narayanasamy A, Vellingiri B. Recent advances in radiotherapy and its associated side effects in cancer—a review. JoBAZ 2019;80. [DOI: 10.1186/s41936-019-0083-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
13 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
14 Akkiz H, Carr BI, Kuran S, Karaoğullarından Ü, Üsküdar O, Tokmak S, Arslan B, Doran F, Balli HT, Ülkü A, Akçam TA, Bahçeci Hİ, Polat KY, Örmeci N, Şimşek H, Sonsuz A, Demir A, Altıntaş E, Demir M, Yalçın K, Ekinci N, Harmancı Özakyol A, Yücesoy M, Uygun A, Guerra V, Delik A, Tokat Y, Yilmaz S, Bektaş A, Kılıç M. Macroscopic Portal Vein Thrombosis in HCC Patients. Can J Gastroenterol Hepatol. 2018;2018:3120185. [PMID: 30009156 DOI: 10.1155/2018/3120185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
15 Lee V, Seong J, Yoon S, Wong T, Wang B, Zhang J, Chiang C, Ho P, Dawson L. Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology 2019;31:560-9. [DOI: 10.1016/j.clon.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 29.6] [Reference Citation Analysis]
17 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
18 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
19 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
20 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Yip CS, Yang X. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Tumour Biol 2017;39:1010428317695030. [PMID: 28349781 DOI: 10.1177/1010428317695030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
22 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Yen YH, Li WF, Kee KM, Wang CC, Cheng YF, Wang JH, Lu SN, Hung CH. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbecks Arch Surg 2021. [PMID: 34825277 DOI: 10.1007/s00423-021-02370-y] [Reference Citation Analysis]
24 Covey AM, Hussain SM. Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. American Journal of Roentgenology 2017;209:67-76. [DOI: 10.2214/ajr.17.17799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
25 Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. Radiology. 2014;272:284-293. [PMID: 24708192 DOI: 10.1148/radiol.14131946] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 9.4] [Reference Citation Analysis]
26 Chen MY, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Tsang NM, Chan KM, Lee WC. Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int 2016;2016:6017406. [PMID: 27999803 DOI: 10.1155/2016/6017406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
27 Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther. 2016;9:3841-3848. [PMID: 27390524 DOI: 10.2147/ott.s104307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
28 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
29 Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, Nath LR. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem 2021;45:e13761. [PMID: 34028054 DOI: 10.1111/jfbc.13761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Radunz S, Saner FH, Treckmann J, Rekowski J, Theysohn JM, Müller S, Best J, Sotiropoulos GC, Paul A, Benkö T. Hepatic artery and biliary complications in liver transplant recipients with radioembolization bridging treatment for hepatocellular carcinoma. Clin Transplant 2017;31. [PMID: 28836737 DOI: 10.1111/ctr.13096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, Minamino T, Watanabe M, Kokubu S, Koizumi W. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84. [PMID: 24886354 DOI: 10.1186/1471-230x-14-84] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
32 Ortega López N. PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. PET Clin 2015;10:507-17. [PMID: 26384597 DOI: 10.1016/j.cpet.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, Kim E. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. Journal of Vascular and Interventional Radiology 2016;27:812-821.e2. [DOI: 10.1016/j.jvir.2016.01.147] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
34 Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8:8867-8876. [PMID: 27780939 DOI: 10.18632/oncotarget.12817] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
35 Kwok PC, Leung KC, Cheung MT, Lam TW, Szeto LT, Chou SQ, Chia NH, Tong CM, Yuen PK, Cheung CH, Law CK. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres. J Gastroenterol Hepatol 2014;29:1897-904. [PMID: 24734957 DOI: 10.1111/jgh.12621] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
36 Wu B, Zhang Y, Tan H, Shi H. Value of 18F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:2430-5. [PMID: 30944961 DOI: 10.1007/s00261-019-01997-2] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med. 2016;57:509-516. [PMID: 26742711 DOI: 10.2967/jnumed.115.167338] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
38 Mendiratta-lala M, William M, Shampain K, Zhang A, Jo A, Moorman S, Aslam A, Mature K, Davenport M. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiology: Imaging Cancer. 2020;2. [PMID: 33778692 DOI: 10.1148/rycan.2020190024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Oncotarget 2015;6:41383-97. [PMID: 26515591 DOI: 10.18632/oncotarget.5510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
40 Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma. PET Clinics 2019;14:459-67. [DOI: 10.1016/j.cpet.2019.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Kaufmann S, Schulze M, Spira D, Horger M. Modern multimodality diagnosis of portal vein infiltration in hepatocellular carcinoma and expected changes during current therapies. Acta Radiol 2015;56:1283-92. [DOI: 10.1177/0284185114556305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
44 Filippi L, Di Costanzo GG, D’agostini A, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nuclear Medicine Communications 2018;39:845-52. [DOI: 10.1097/mnm.0000000000000879] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
45 Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W, Yang GS, Cheng H, Hu H, Gao C, Guo J, Li A, Meng Y, Jiang X, Yang Y, Qian G, Luo M, Hu B, Man X, Zhang B, Su C, Zhou F, Li N, Shi J, Wang M, Zheng Y, Guo W, Sun J, Wang H, Lau WY, Wu MC. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 2016;7:40816-29. [PMID: 27027235 DOI: 10.18632/oncotarget.8386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
46 Kawagishi N. HCC with portal vein tumor thrombosis: how to manage? Hepatol Int 2020;14:609-11. [PMID: 32949378 DOI: 10.1007/s12072-020-10090-6] [Reference Citation Analysis]
47 Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging 2014;41:634-8. [DOI: 10.1007/s00259-013-2674-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
48 Zhu P, Liao Y, Fan J, Li X, Su L, Li J, Yuan S, Yu J, Liao W. Preoperative prediction of hepatocellular carcinoma with portal vein tumor thrombus based on conventional data. Oncotarget. 2017;8:104227-104237. [PMID: 29262635 DOI: 10.18632/oncotarget.22198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
50 Lu J, Guo J, Zhu H, Zhu G, Chen L, Teng G. Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. Journal of Vascular and Interventional Radiology 2017;28:786-794.e3. [DOI: 10.1016/j.jvir.2017.02.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
51 Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943. [PMID: 26943239 DOI: 10.1259/bjr.20150943] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
52 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
53 Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl 2019;25:207-16. [PMID: 30246323 DOI: 10.1002/lt.25345] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
54 Akinwande O, Kim D, Edwards J, Brown R, Philips P, Scoggins C, Martin RC 2nd. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015;24:270-275. [PMID: 26133576 DOI: 10.1016/j.suronc.2015.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
55 Chung SR, Kim JH, Yoon HK, Ko GY, Gwon DI, Shin JH, Song HY, Ko HK, Yoon SM. Combined Cisplatin-Based Chemoembolization and Radiation Therapy for Hepatocellular Carcinoma Invading the Main Portal Vein. J Vasc Interv Radiol. 2015;26:1130-1138. [PMID: 26119202 DOI: 10.1016/j.jvir.2015.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
56 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
57 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
58 Delicque J, Boulin M, Guiu B, Pelage J, Escal L, Schembri V, Assenat E, Fohlen A. Interventional oncology for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:530-7. [DOI: 10.1016/j.clinre.2016.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
59 Abdelmaksoud AH, Mandooh S, Nabeel MM, Elbaz TM, Shousha HI, Monier A, Elattar IA, Abdelaziz AO. Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients. Asian Pac J Cancer Prev 2017;18:183-8. [PMID: 28240515 DOI: 10.22034/APJCP.2017.18.1.183] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
61 Tsai WL, Lai KH, Liang HL, Hsu PI, Chan HH, Chen WC, Yu HC, Tsay FW, Wang HM, Tsai HC, Cheng JS. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One 2014;9:e92784. [PMID: 24824520 DOI: 10.1371/journal.pone.0092784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
62 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther 2017;10:4773-85. [PMID: 29033589 DOI: 10.2147/OTT.S137519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
64 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
65 Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, Regnault H, Amaddeo G, Itti E, Luciani A, Kobeiter H, Tacher V. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44. [PMID: 33012693 DOI: 10.1016/j.diii.2020.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
67 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021. [PMID: 34355489 DOI: 10.1002/lt.26257] [Reference Citation Analysis]
68 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
69 Zhang JY, Xu D, Liu ZZ, Li Y, Wang LJ, Xing BC. Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. Chin Med J (Engl) 2017;130:470-6. [PMID: 28218222 DOI: 10.4103/0366-6999.199839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
70 Lorenzin D, Pravisani R, Leo CA, Bugiantella W, Soardo G, Carnelutti A, Umberto B, Risaliti A. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. Cancer Biotherapy and Radiopharmaceuticals 2016;31:65-9. [DOI: 10.1089/cbr.2015.1905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Chui AMN, Yau TCC, Cheung TT. An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system. Glob Health Med 2020;2:312-8. [PMID: 33330826 DOI: 10.35772/ghm.2020.01062] [Reference Citation Analysis]
72 Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, Wong YH, Leung TWT. Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging 2018;45:2110-21. [DOI: 10.1007/s00259-018-4064-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
73 Luo J, Zhang Z, Liu Q, Zhang W, Wang J, Yan Z. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol Int 2016;10:185-95. [DOI: 10.1007/s12072-015-9663-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
74 Miller FH, Lopes Vendrami C, Gabr A, Horowitz JM, Kelahan LC, Riaz A, Salem R, Lewandowski RJ. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021;41:1802-18. [PMID: 34559587 DOI: 10.1148/rg.2021210014] [Reference Citation Analysis]
75 Lué A, Serrano MT, Bustamante FJ, Iñarrairaegui M, Arenas JI, Testillano M, Lorente S, Gil C, de la Torre M, Gomez A, Sangro B. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget 2017;8:103077-86. [PMID: 29262546 DOI: 10.18632/oncotarget.21528] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
76 Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19:868-879. [PMID: 25001265 DOI: 10.1634/theoncologist.2014-0097] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
77 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
78 Sun JX, Shi J, Li N, Guo WX, Wu MC, Lau WY, Cheng SQ. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med 2016;13:452-8. [PMID: 28154776 DOI: 10.20892/j.issn.2095-3941.2016.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
79 Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol 2017; 23(43): 7735-7745 [PMID: 29209114 DOI: 10.3748/wjg.v23.i43.7735] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
80 Liang H, Cui P, Guo Q, Mao X, Wen F, Sun W, Shan M, Lu Z. Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. Asia Pac J Clin Oncol 2017;13:e331-41. [PMID: 28078806 DOI: 10.1111/ajco.12606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:e35-e40. [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
82 Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, Park CH, Kim HS, Choi SK, Rew JS. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) 2017;96:e6745. [PMID: 28445298 DOI: 10.1097/MD.0000000000006745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
83 Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, Yang MJ, Wang JH, Chen B, Zeng SC, Luo JJ, Liu LX, Yan ZP. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget 2017;8:12108-19. [PMID: 28076848 DOI: 10.18632/oncotarget.14520] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
84 Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW. Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. Onco Targets Ther 2015;8:3457-64. [PMID: 26640386 DOI: 10.2147/OTT.S92473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
85 Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nagano T, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Hoshi A, Kurosaki M, Izumi N. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res 2020;50:1375-85. [DOI: 10.1111/hepr.13567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
86 Jin J, Zhu P, Liao Y, Li J, Liao W, He S. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget 2015;6:19217-27. [PMID: 26057470 DOI: 10.18632/oncotarget.4265] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
87 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
88 Sun H, Zhang M, Liu R, Liu Y, Hou Y, Wu C. Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol. 2018;14:1165-1176. [PMID: 29334777 DOI: 10.2217/fon-2017-0354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
89 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
90 Que J, Wu HC, Lin CH, Huang CI, Li LC, Ho CH. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine (Baltimore) 2020;99:e19660. [PMID: 32221093 DOI: 10.1097/MD.0000000000019660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
92 Kim JH, Shim JH, Yoon HK, Ko HK, Kim JW, Gwon DI. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int 2018;38:1646-54. [PMID: 29436101 DOI: 10.1111/liv.13719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
93 Sun J, Yang L, Shi J, Liu C, Zhang X, Chai Z, Lau WY, Meng Y, Cheng SQ. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial. Radiother Oncol 2019;140:20-5. [PMID: 31176205 DOI: 10.1016/j.radonc.2019.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
94 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
95 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
96 Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol 2016;7:433-40. [PMID: 27284477 DOI: 10.21037/jgo.2015.10.04] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
97 Elbanna KY, Khalili K, O’malley M, Chawla T. Imaging and implications of tumor thrombus in abdominal malignancies: reviewing the basics. Abdom Radiol 2020;45:1057-68. [DOI: 10.1007/s00261-019-02282-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol 2015; 7(11): 1553-1561 [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
100 Chen QF, Li W, Yu SC, Chou YH, Rhim H, Yang X, Shen L, Dong A, Huang T, Huang J, Zhang F, Fan W, Zhao M, Gu Y, Huang Z, Zuo M, Zhai B, Xiao Y, Kuang M, Li J, Han J, Song W, Ma J, Wu P. Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. Front Oncol 2021;11:621834. [PMID: 34277397 DOI: 10.3389/fonc.2021.621834] [Reference Citation Analysis]
101 Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma. J Dig Dis 2020;21:287-92. [PMID: 32315498 DOI: 10.1111/1751-2980.12866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
102 Carr BI, Guerra V. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci 2016;61:937-47. [PMID: 26576554 DOI: 10.1007/s10620-015-3922-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
103 Powerski MJ, Scheurig-Münkler C, Hamm B, Gebauer B. Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies. J Med Imaging Radiat Oncol 2014;58:472-80. [PMID: 24964737 DOI: 10.1111/1754-9485.12187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
104 Chacko S, Samanta S. "Hepatocellular carcinoma: A life-threatening disease". Biomed Pharmacother. 2016;84:1679-1688. [PMID: 27823920 DOI: 10.1016/j.biopha.2016.10.078] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]